Back to top

Hologic (HOLX) Beats Earnings and Revenue Estimates in Q3

Read MoreHide Full Article

Hologic, Inc. (HOLX - Free Report) reported third-quarter fiscal 2018 adjusted earnings per share (EPS) of 58 cents, up 16% year over year and above the company’s 55-57 cents guidance. Adjusted EPS beat the Zacks Consensus Estimate of 56 cents.

On a reported basis, the company recorded net income of 41 cents per share as compared with 21 cents in the year-ago quarter.

Revenues in Detail

Revenues grossed $824 million in the quarter, up 2.2% year over year (up 1.1% at constant exchange rate or CER). The top line surpassed the Zacks Consensus Estimate of $800.1 million and the company’s guidance of $795-$810 million.

Solid contributions from Breast Health and international businesses drove the top line.

Hologic, Inc. Price, Consensus and EPS Surprise

 

Geographically, revenues in the United States declined 0.3% year over year to $616.8 million. However, the company saw sequential improvement in Breast Health, Diagnostics and Surgical businesses in the United States. International revenues were up 10.5% (up 5.5% at CER) to $207.2 million, primarily on strong contribution from the Breast Health business.

Segments in Detail

Revenues at the Diagnostics segment (35.7% of total revenues) rose 3.6% year over year (up 2.3% at CER) to $294.3 million in the third quarter. Under this segment, Molecular Diagnostics revenues of $154.5 million increased 7.3% (6.3% at CER). Global growth at Molecular Diagnostics was primarily driven by new product revenues along with continued solid uptake of Aptima women's health products. The company is also seeing strong demand for the virology tests.

Cytology and Perinatal revenues of $121.1 million showed an improvement of 0.1% (down 1.8% at CER).

Revenues at the Breast Health segment (37.4%) rose 8.5% (up 7.4% at CER) to $307.9 million. Revenues in the United States grew 4.4%. The upside was led by higher service and new product revenues. International revenues however climbed 26.1% (20.5% at CER) year over year, marking the fourth consecutive quarter of growth of more than 20%.

Revenues at the GYN Surgical business (13.1%) were up 1.1% (up 0.3% at CER) to $107.7 million. Medical Aesthetic business in the quarter reported revenues of $91.7 million, reflecting 11.1% of total revenues. Revenues at Skeletal Health (accounting for the rest) increased 3.2% (up 2.1% at CER) to $22.5 million.

Operational Update

In the fiscal third quarter, Hologic’s gross margin expanded 210 basis points (bps) to 52.9%. Adjusted gross margin fell 50 bps to 62.6% due to the divestiture of blood screening business, geographic mix and revenues from low-margin Cynosure products.

Hologic’s adjusted operating expenses amounted to $279 million, up 1.5% year over year. Adjusted operating margin contracted 20 bps to 28.8%.

Financial Update

Hologic exited third-quarter fiscal 2018 with cash and cash equivalents of $575.4 million, compared $614.2 million at the end of second-quarter fiscal 2018. Total long-term debt was $2.72 billion at the end of the reported quarter, compared with $2.74 billion in second-quarter fiscal 2018.

During the nine months ended Jun 30, 2018, the company generated operating cash flow of $500.5 million, against the cash used in operating activities of $158.3 million in the year-ago period. 

Guidance

Hologic has updated its fiscal 2018 financial guidance. The company currently expects adjusted revenues of $3.21-$3.22 billion, compared with the previous range of $3.18-$3.21 billion. The company expects revenues to grow in the range of 3.9-4.4% compared with the previously provided range of 2.7-3.7% at CER. The Zacks Consensus Estimate for revenues is pinned at $3.20 billion, below the guided range.

The company currently expects adjusted EPS of $2.24-$2.26, compared with the previous range of $2.22-$2.27. The Zacks Consensus Estimate for adjusted EPS is pegged at $2.23, below the guided range.

For fourth-quarter fiscal 2018, Hologic expects adjusted revenues of $800-$815 million, representing annualized decline of 4% to annualized growth of 1.5% at CER. The Zacks Consensus Estimate for revenues stands at $817.2 million, above the projected range.

Adjusted EPS is estimated at 58-60 cents, reflecting an annualized growth of 16-20%. The Zacks Consensus Estimate for third-quarter adjusted EPS is pinned at 60 cents, coinciding with the high end of the company’s guidance.

Our Take

Hologic exited third-quarter fiscal 2018 on a solid note. Solid performance by the international business buoys optimism. Also, the improvement in the Surgical and Cynosure businesses is encouraging. Management seems to be upbeat about completing the buyout of Faxitron Bioptics, a privately-held leader in digital specimen radiography.

However, the blood screening divestiture is also likely to impede growth for the company. Moreover, the company expects revenues from the Cynosure business to decline on a sequential basis due to seasonality and FDA-related issues on MonaLisa Touch.

Zacks Rank & Key Picks

Hologic carries a Zacks Rank #4 (Sell).

Some better-ranked stocks in the broader medical sector which reported solid results this earnings season are Intuitive Surgical (ISRG - Free Report) , Chemed Corporation (CHE - Free Report) and Align Technology, Inc. (ALGN - Free Report) . While Intuitive Surgical sports a Zacks Rank #1 (Strong Buy), Chemed and Align Technology carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Intuitive Surgical reported second-quarter 2018 adjusted EPS of $2.76, which beat the Zacks Consensus Estimate of $2.48. Revenues totaled $909.3 million, also surpassing the consensus estimate of $870 million.

Align Technology posted second-quarter 2018 adjusted EPS of $1.30, steering past the Zacks Consensus Estimate of $1.09. Revenues came in at $490.3 million, beating the consensus estimate of $462.9 million.

Chemed reported second-quarter 2018 adjusted EPS of $2.81, which trumped the Zacks Consensus Estimate of $2.68. Revenues of $441.8 million edged past the Zacks Consensus Estimate of $432.3 million.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>



More from Zacks Analyst Blog

You May Like